- New guidelines from the American Society of Clinical Oncology (ASCO) recommend that women with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (eBCa) who are >50 years may skip chemotherapy if their Oncotype DX recurrence score (RS) is in the intermediate range (11-25) or lower.
- Women age TAILORx trial found a small benefit for this age group.
Why this matters
- This is the first guideline to reflect results of the pivotal TAILORx trial on the use of genetic biomarkers to guide treatment decisions.
- Expert panel was convened to review the TAILORx trial, along with related published literature.
- Low RS was 1-10; intermediate RS was 11-25; high RS was 26-100.
- Funding: ASCO.
- Recommendation 1: age groups that may forego chemotherapy, but not endocrine therapy alone.
- Patients >50 years with RS
- Patients ≤50 years with RS
- Recommendation 2:
- Patients ≤50 years with RS 16-25 may be offered chemoendocrine therapy.
- Recommendation 3:
- Patients of any age with RS >30 should be considered for chemoendocrine therapy.
- Recommendation 4:
- Patients of any age with RS 26-30 may be offered chemoendocrine therapy.
- No confirmation of TAILORx results.